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Abbreviations 
3-HK 3-hydroxykynurenine 
7-C1-KYNA 7-chlorokynurenic acid 
ANA anthranilic acid 
ATP adenosine triphosphate 
BBB blood-brain barrier 
CSF cerebrospinal fluid 
EAA excitatory amino acid 
GABA y-aminobutyric acid 
G-KYNA glucosamine conjugate of kynurenic acid 
i.c.v. intracerebroventricularly 
IDO indolamine 2,3-dioxygenase 
i.p. intraperitoneally 
i.v. intravenously 
KAT II kynurenine aminotransferase II 
KP kynurenine pathway 
KYN kynurenine 
KYNA kynurenic acid 
LTP long-term potentiation 
MI primary motor cortex 
MIc contralateral primary motor cortex 
Ml, ipsilateral primary motor cortex 
nACh nicotinic acetylcholine 
NAD nicotinamide adenine dinucleotide 
NMDA N-methyl-D-aspartate 
PND postnatal day 
PROB probenecid 
PTZ pentylenetetrazole 
QUIN quinolinic acid 
TRP tryptophan 
Summary 
The kynurenine pathway is the main pathway of the tryptophan metabolism. This metabolic 
cascade is well known to be responsible for nicotinamide adenine dinucleotide and 
nicotinamide adenine dinucleotide phosphate which participate in basic cellular processes. 
Some 25 years ago, it was found that intermediates of this pathway have neuroactive 
properties. 
The central compound is the L-kynurenine which in turn can be converted to the excitatory 
amino acid receptor antagonist kynurenic acid or the N-methyl-D-aspartate receptor agonist 
quinolinic acid. 
Quinolinic acid is a neurotoxic agent which can augment the overexcitation of these receptors 
and can therefore cause neuronal damage. It has similar neurotoxic effects to those of 
glutamate in the neocortex, striatum and hippocampus. This glutamate-mediated excitotoxic 
damage can cause abnormalities in cellular Ca2t homeostasis, elevated production of reactive 
oxygen species, and induce lipid peroxidation, too. 
These processes of cell damage may be prevented by using another metabolite of this 
pathway, the kynurenic acid. 
Kynurenic acid which is one of the few, known endogenous broad-spectrum antagonist of 
excitatory amino acid receptors, especially the N-methyl-D-aspartate receptors, behaves as a 
neuroprotective agent: it can inhibit the overexcitation of these receptors by binding the 
glycine allosteric site. Mor eover, kynurenic acid non-competitively blocks the activity of 
presynaptic a7-nicotinic acetylcholine receptors. 
Changes in the absolute or relative concentration of these compounds i.e. disturbances of the 
kynurenine pathway in the brain have been implicated in numerous neurodegenerative 
disorders, such as stroke, epilepsy, ischemia, Alzheimer's and Huntington's diseases, AIDS, 
multiple sclerosis, encephalopathies, anxiety, depression and schizophrenia. 
It is extremely important that the kynurenine pathway abnormality should be suitably 
prevented or corrected which could attenuate the pathological processes. 
Therapeutic use of kynurenic acid is difficult enough since it has a very limited ability to cross 
the blood-brain barrier. The aim is to develop different analogues of kynurenic acid which can 
6 
readily cross the barrier and display similar effectiveness on the affected receptors to that of 
kynurenic acid. 
Another possibility may be the use of its prodrug, L-kynurenine, which can pass the blood-
brain barrier easily, and through the action of kynurenine aminotransferase, can increase the 
brain level of kynurenic acid. 
First, we examined the effect of a relatively high dose of L-kynurenine which might 
lead to an elevated concentration of kynurenic acid in the brain. This effect can be augmented 
by using probenecid, which prevents the discharge of the organic acids from the cerebrospinal 
fluid. This proved effective: 300 mg/kg kynurenine administered intraperitoneally slightly 
decreased the population spike amplitude of the CA1 pyramidal cell responses. Probenecid 
had a stronger effect with a longer delay: 2 h after the drug injection the amplitude of the 
evoked potentials marked decreased. 
Two compounds administered together resulted in a significant and progressive decrease in 
amplitude of the population spike evoked on the CA1 pyramidal cells already 30 min after the 
administration. This effect is probably based on the inhibition of the N-methyl-D-aspartate 
receptors of the CA1 pyramidal cells by the elevated level of kynurenic acid in the brain 
tissue, as a consequence of peripheral kynurenine and probenecid administration. 
Pentylenetetrazole is often used experimentally to induce seizures which mimic generalized 
clonic seizures in humans. 60 mg/kg of this drug, administered intraperitoneally to 
anaesthetized rats, resulted in a significant increase in amplitude of the CA1 spike activity. In 
some cases, this increase reached the 200% of the control level. 
This effect of pentylenetetrazole was completely compensated by pretreatment with 
kynurenine+probenecid. 
In parallel with the electrophysiological results, we studied the behavioral effects of 
kynurenine administered together with probenecid 2 h before the pentylenetetrazole injection. 
This convulsive dose of pentylenezetrazole (60 mg/kg) caused epileptic seizures and death in 
awake animals. It was found that kynurenine and probenecid pretreatment completely protects 
awake rats from pentylenetetrazole-induced clonic-tonic seizures and death. Although they 
exhibited reduced rearing, washing and defecation activity, we did not observe any difference 
in behavior between the controls and the treated animals in the open-field arena. In the water-
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maze task, kynurenine+probenecid+pentylenetetrazole-treated animals revealed a significantly 
impaired performance. 
It is well known that kynurenic acid can cross the blood-brain barrier only very poorly; 
hence, its use as a neuroprotective agent is rather difficult. The Department of Comparative 
Physiology and the Institute of Medical Chemistry at the University of Szeged have developed 
a new kynurenic acid analogue, glucoseamine conjugate of kynurenic acid, which probably 
can readily cross the blood-brain barrier, separate glucosamine and kynurenic acid in the 
brain, and increase the kynurenic acid level in the central nervous system. 
To check the similar effects, we tested these drugs in behavioral and electrophysiological 
tasks, too. 
in agreement with the literature findings, the behavioral experiments revealed that 
intracerebroventricularly microinjected kynurenic acid induces stereotype behaviour and 
ataxia. Similar changes in behaviour were found after equimolar administration of 
glucosamine kynurenic acid. 
To examine whether glucosamine kynurenic acid can pass the blood-brain barrier, we 
administered this drug intravenously and intraperitoneally in the electrophysiological tests. 
Kynurenic acid administered systemically in doses of 17, 34, 68 or 136 pmol/kg did not cause 
any observable change in the electrophysiological activity of the hippocampal CA1 region in 
anaesthetized animals. Against this, glucosamine kynurenic acid in a dose of 136 pmol/kg 
resulted in the death of the animals in all cases, while a dose of 68 pmol/kg administered 
intravenously induced the stoppage of breathing of the animals, though they could be 
resuscitated. A dose of glucosamine kynurenic acid as small as 17 pmol/kg was effective in 
reducing the CA3 stimulation-evoked activity of the CA1 pyramidal cells in the hippocampus. 
This effect was augmented when glucosamine kynurenic acid was administered together with 
probenecid. 
N-methyl-D-aspartate receptors play an important role in spatial learning and working 
memory. The perinatal blockade of these receptors might have behavioral consequences when 
tests are made at a more advanced age. In the course of our working, we tested the hypothesis 
whether even a minimal conflict with the N-methyl-D-aspartate receptors in the early critical 
age of life, which results in mild detectable change in daily behaviour, induces hidden but life-
long dysfunctions that can be detected in different parts of the central nervous system. We 
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chose a low dose of MK-801 (0.1 mg/kg), injecting twice a day on postnatal days 7-19, which 
caused a slight, not significant impairment of the performance in the water-maze task. Later, 
these animals were used in electrophysiological examinations. 
An increasing number of results suggest that transiently reduced inhibition (e.g. after nerve 
injury) is a necessary, but not sufficient condition for the development of motor cortex 
plasticity. The potential for plasticity in the motor cortex has been closely linked to the 
function of N-methyl-D-aspartate receptors. Simple recordings of evoked potentials in this 
cortex did not reveal significant differences between the controls and the MK-801-treated 
animals. Therefore, we tested a more complex phenomenon. The plasticity of evoked 
responses induced by facial nerve injury can be tested by the paired pulse paradigm. In the 
control rats, the responses evoked in the motor cortex of both hemispheres by continuous 1-Hz 
trigeminal stimulation were facilitated after facial nerve transection. This was not the case 
with the MK-801-treated animals. In a majority of cases, the evoked responses did not change, 
while in 40% of the cases, continuous stimulation reduced the evoked responses recorded after 
facial nerve injury. 
These results and the related literature indicate the importance of the normal function of the 
kynurenine pathway and the possibilities of neuroprotection with kynurenine derivatives. 
Elevated levels of kynurenic acid or its analogues in the brain may reduce the overactivation 
of excitatory amino acid receptors and may modify or arrest the progression of various 
neurodegenerative disorders. This can offer a novel therapeutic opportunity where the 
development of these compounds promises a key for brain neuroprotection. 
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Introduction 
The kynurenine (KYN) pathway (KP) is the main pathway of the tryptophan (TRP) 
metabolism. All the metabolites of the KP are derived directly or indirectly from KYN, which 
is the major degradation product of TRP (Fig. 1). 
This metabolic cascade is well known to be responsible for nicotinamide adenine dinucleotide 
(NAD) and NAD-phosphate, which participate in basic cellular processes. 
Some 25 years ago, it was found that intermediates in the KP have neuroactive properties. It 
was demonstrated that convulsions appeared in mice after they received quinolinic acid 
(QUIN) intraeerebroventricularly (i.c.v.) (Lapin, 1978). In the same year, the quantitative 
analysis of L-KYN was investigated by using high-pressure liquid chromatography. It was 
found that KYN was formed from TRP in the brain (40%) and was also taken up from the 
periphery (60%). The rate of cerebral KYN synthesis was 0.29 nmol/g/h (Gal and Sherman, 
1978). Moreover, it is well known that KYN can easily cross the blood-brain barrier (BBB) 
with the aid of neutral amino acid carriers (Fukui et al., 1991). 
Lapin was one of the pioneers of studies of the KYN pathway and its metabolites. In 1973, he 
presumed that KYNs are probable participants in depression (Lapin, 1973). Furthermore, L-
KYN plays an important role in the modulation of female sexual behaviour: lordosis was 
facilitated in oestrogen-primed ovariectomized rats by the administration of L-KYN into the 
ventricles (Mendelson et al1987). 
The L-KYN derivative QUIN (Fig. 1) is a selective ligand of the N-methyl-D-aspartate 
(NMDA) receptor (Stone and Perkins, 1981), which can therefore cause neuronal damage 
(Schwarcz et al., 1984). It has similar neurotoxic effects to those of glutamate in the 
neocortex, striatum and hippocampus (Perkins and Stone, 1983). 
It was already hypothesized in 1983 that QUIN plays an important role in Huntington's 
disease (Schwarcz et al., 1983). Three years later, Beal et al. proved that the injection of 
QUIN into the rat striatum duplicated the neurochemical features of this disorder (Beal et al., 
1986). 
The convulsant and neurodegenerative properties of QUIN are especially pronounced in the 
hippocampus (Schwarcz et al., 1987; Tsuzuki et al., 1989b). The QUIN-induced 
depolarization and burst firing of the CA1 pyramidal neurons are Ca2"-dependent (Peet et al., 
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1986) and QU1N can cause a marked increase in the intracellular Ca2 ' concentration even after 
the voltage-dependent Ca2+ channels have been suppressed (Tsuzuki et al., 1989a). 
Intrastriatal injection of QUIN induces a substantial neuronal loss, which is potentiated by the 
administration of 3-hydroxykynurenine (3-HK) (Guidetti and Schwarcz, 1999). It produces 
early changes in the activity of the striatal neurons and movements of several cations, which 
may contribute to subsequent abnormalities in energy metabolism and to cell death (Bordelon 
et al, 1998). 
Bilateral intrastriatal microinjection of QUIN induced hyperactivity and weight loss (Sanberg 
et al, 1989), increased nocturnal locomotor activity (Bazzett et al, 1996) and abnormal 
feeding behaviour (Giordano et al., 1990). Furthermore, QUIN-lesioned animlas displayed an 
impaired acquisition in the visuospatial skills, in the transfer of learning and in the retrieval of 
stored memories in the Morris water-maze test (Furtado and Mazurek, 1996; Joel et al, 1998; 
Francis et al, 2000), and in the spatial learning in the radial-maze test (Shear et al, 1998). 
The other important metabolite of KP is kynurenic acid (KYNA) (Fig.l), which is one 
of the few, known endogenous broad-spectrum antagonists of excitatory amino acid (EAA) 
receptors (Swartz et al, 1990), especially the NMDA receptors. KYNA behaves as a 
neuroprotective agent: it can inhibit the overexcitation of these receptors by binding the 
glycine allosteric site, it may therefore influence physiological and pathological processes, so 
it has therapeutic effects in numerous neurological disorders (Stone, 2000; Stone, 2001; Stone 
et al, 2003). Furthermore, KYNA displays neuroinhibitory properties in neurophysiological 
experiments (Perkins and Stone, 1982) and, like other glutamate receptor antagonists, can 
cause impairments in learning and behaviour (Morris et al., 1986). 
An early study revealed that the 2-carboxy and 4-hydroxy groups of KYNA (Fig. 1) are 
essential for the antagonist activity (Robinson et al, 1985). 
In 1988, Moroni et al. reported that the concentration of KYNA in the mammalian brain is in 
the range 10-150 nmol (Moroni et al., 1988), and some years later pharmacological studies 
proved that KYNA is derived in most brain regions primarily from kynurenine 
aminotransferase II (KAT II) activity (Guidetti et al, 1997), which is located mainly in the 
glia (Du et al, 1992). The glia has uptake mechanisms for KYN and the ability to release 
KYNA (Turski et al, 1989; Speciale and Schwarcz, 1990). KAT II operates best at 
physiological pH and preferentially recognizes KYN as substrate (Okuno et al., 1991). L-
Cysteine sulphinate, an endogenous sulphur-containing amino acid, inhibits the activity of 
KAT II, decreases the KYNA production in the brain and has a higher potency than that of any 
other known KAT II inhibitor (Kocki et ai, 2003). 
Moreover, KYNA non-competitively blocks the activity of presynaptic a7-nicotinic 
acetylcholine (nACh) receptors and can increase the expression of non-a7-nACh receptors 
(Hilmas et al., 2001). Cross-talk between KYNA and the nicotinic cholinergic system has 
been presumed to play a role in the pathogenesis of numerous brain disorders, including 
schizophrenia and Alzheimer's disease, in which brain KYNA levels are elevated and 
nicotinic functions are impaired (Alkondon et al., 2004). 
KYNA can suppress spontaneous epileptiform burst discharges (Stone, 1988) and depress the 
amplitude and duration of Mg2+-free bursts (Schneiderman and MacDonald, 1989) in the CA3 
region of hippocampal slices. 
Long-term potentiation (LTP), which is associated with the NMD A receptor function, is 
dramatically enhanced by glycine in area CA1 in slices and this effect can be antagonized by 
KYNA (Tauck and Ashbeck, 1990). Additionally, NMDA receptor blockers reversibly 
blocked the induction of LTP in the commissural/associational pathway, but had no effect on 
mossy fibre LTP (Harris and Cotman, 1986). 
Intraraphe administration of KYNA resulted in marked hyperactivity (Wirtshafter et al., 
1989), while its bilateral administration into the nucleus accumbens increased the number of 
visits to unbaked arms (reference memory errors) (Schacter et al., 1989), impaired the visual 
discrimination and enhanced the motor activity (Ericson et ai, 1990). 
3-HK and anthranilic acid (ANA) (Fig. 1) cause neuronal damage by producing 
oxygen free radicals and raising the levels of oxidative stress and lipid peroxidation. These can 
contribute to the impairment of the mitochondrial function (Lee et al., 2004), including the 
heart mitochondria, which can lead to cardiovascular abnormalities (Baran et al., 2003). 
Moreover, 3-HK may potentiate the neurotoxic effects of QUIN (Guidetti and Schwarcz, 
1999) resulting in neuronal cell death. This may be attenuated by epigallocatechin 3-gallate, a 
major compound in green tea (Jeong et al., 2004). 
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Figure 1. The kynurenine pathway 
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Changes in the absolute or relative concentration of these compounds (in particular KYNA 
and QUIN) in the brain have been implicated in numerous neurodegenerative disorders, e.g. 
stroke, epilepsy, iscbaemia, Alzheimer's and Huntington's diseases, AIDS, multiple sclerosis, 
encephalopathies, anxiety, depression and schizophrenia. An elevated QUIN level or a 
decreased KYNA concentration causes impairment in the cellular energy metabolism by 
overexciting the glutamate receptors, in particular the NMDA receptors. Glutamate-mediated 
excitotoxic damage decreases the voltage-dependent Mg2 ' blockade, and causes abnormalities 
in the cellular Ca2+ homeostasis and the elevated production of reactive oxygen species 
(Greene and Greenamyre, 1996). 
The intrastriatal injection of QUIN (an animal model of Huntington's disease) leads to 
a similar pattern of neuronal death to that seen in this human disease by producing a 
progressive mitochondrial dysfunction, the impairment of cellular energy homeostasis 
(Bordelon el a!., 1997) and major decreases in superoxide dismutase activity. This widely 
used animal model can mimic the diminution of the amplitude of early cortical somatosensory 
(Schwarz et al, 1992) and visual evoked potentials (Schwarz. and Block, 1993) seen in 
Huntington's disease patients. 
Rios and Santamaría demonstrated that QUIN can induce lipid peroxidation, and that 
this effect can be blocked by administration of KYNA (Rios and Santamaría, 1991). Markers 
of lipid peroxidation are found in Alzheimer's disease, implying that QUIN may be one of the 
critical factors in the pathogenesis of neuronal damage in Alzheimer's disease (Guillemin and 
Brew, 2002; Guillemin et al., 2003). Amyloid precursor protein can suppress the elevation of 
intracellular Ca2+ induced by glutamate, suggesting that the cellular Ca2+ homeostasis plays a 
prominent role in the pathogenesis of this disease (Furukawa and Mattson, 1998). 
It is well known that massively released EAAs play a major role in ischaemic neuronal 
degeneration and that KYNA has a neuroprotective effect against ischaemic brain damage. 
Moreover, KYN-3-monooxygenase inhibitors reduce the neuronal death in the CAI region of 
hippocampal slices exposed to 30 min of oxygen and glucose deprivation by decreasing the 
local synthesis of 3-HK and QUIN (Carpenedo et al., 2002). Administration of KYN produces 
a significant increase in the normal and ischaemic corticocerebral blood flow, which can be 
prevented by pretreatment with atropine or N-omega-nitro-L-arginine, suggesting that this 
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process might be mediated by the activation of cholinergic and nitrogen monoxide pathways 
(Sas et al., 2003). 
Even low concentrations of endogenous KYNA can reduce the number of hippocampal 
slices with spontaneous epileptiform discharge after exposure to a buffer lacking Mg2+. It is 
suggested that endogenous KYNA plays an important role in the suppression of seizure-like 
activity (Scharfman et al., 2000). Furthermore, in a genetic model of absence epilepsy, a 
significantly lower concentration of KYNA was found in the frontal cortex than in the non-
epileptic control (Kaminski et al., 2003). A dysfunction of the serotoninergic system, 
including the KP, has been found in patients with temporal lobe epilepsy (Natsume et al., 
2003) or with the tuberous sclerosis complex (Fedi et al., 2003). 
An abnormality of the KP has also been found in neuropsychiatry: a disturbed 
metabolism of TRP affects the biosynthesis of the neurotransmitter 5-hydroxytriptamine and 
this appears to be associated with an increased susceptibility to depression. The activation of 
indolamine 2,3-dioxygenase (IDO) (Fig. 1) could be an important link between the 
immunological network and the pathogenesis of depression (Widner et al., 2002), while 
reduced TRP availability plays a role in interferon-alpha-induced depressive symptoms 
(Capuron et al., 2003). In schizophrenic patients an elevated level of endogenous KYNA may 
be demonstrated (Erhardt and Engberg, 2002). 
It is extremely important that the KP abnormality should be suitably prevented or corrected 
which could attenuate the pathological processes (mentioned above). 
There are at least two ways in which therapeutic agents are being developed with the aim of 
modulation of the KP. 
One approach is to use analogues of KYNA as antagonists at glutamate receptors, 
because KYNA is able to pass the BBB only poorly, which hampers its use. The aim here is to 
develop different analogues of KYNA which can readily cross the BBB and display similar 
effectiveness on the affected receptors to that of KYNA. 
The second approach to fend off the effects of a KP disturbance is to use enzyme 
inhibitors which can decrease the activities of the enzymes that facilitate the QUIN formation. 
These enzyme inhibitors can therefore shift the KP towards the neuroprotective KYNA and 
inhibit the accumulation of QUIN and other neurotoxic metabolites. 
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Some synthetic KYNA derivatives can behave as antagonists of NMDA receptors and provide 
an attractive strategy for the development of novel neuroprotective and anticonvulsive agents. 
7-chloro-KYNA (7-C1-KYNA) is a potent selective antagonist at the glycine site (Kemp et al., 
1988), but its penetration through the BBB is poor. Its prodrug, 4-chloro-KYN (Wu et ah, 
1997a), readily enters the brain from the circulation and prevents QUIN-induced neurotoxicity 
in the rat hippocampus (Wu et al, 2000) and striatum (Lee and Schwarcz, 2001) after 
systemic administration. 7-C1-KYNA depresses or completely blocks the NMDA receptor-
mediated synaptic transmission in a Mg2+-free medium and the induction of LTP in a Mg2 ' -
containing medium in the CA1 region of rat hippocampal slices (Bashir et al, 1990; Izumi et 
al, 1990; Thiels et al, 1992), and it also inhibits the induction of LTP following tetanic 
stimulation (Watanabe et al, 1992; Ikegaya et al, 1995). A similar effect was observed in the 
neonatal rat hippocampus, related with theta burst stimulation (Oliver et al., 1990). 
D-glucose or D-galactose esters of 7-chloro-KYNA have been synthetized to facilitate the 
transport of 7-C1-KYNA across the BBB (Battaglia et al, 2000). 
The following aims were set during our work on this topic: 
To establish 
• whether L-KYN, which can cross easily the BBB and can be transformed into 
neuroprotective KYNA in the brain, can act against the epileptic seizures induced 
by pentylenetetrazole (PTZ); 
• whether L-KYN administered intraperitoneally (i.p.) together with probenecid 
(PROB), a known inhibitor of the transport of organic acid from the cerebrospinal 
fluid (CSF), can be more effective than KYN administered alone and whether they 
are able to protect against the neurotoxic effect of PTZ; 
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whether the newly synthetized glucosamine-kynurenic acid (G-KYNA) 
administerd i.e.v. has similar neuroprotective effects on the NMDA receptor 
complex to those of KYNA; 
whether systemically administered G-KYNA is able to cross the ÛBB and can be 
more effective than KYNA injected i.p.; 
whether neonatal treatment with MK-801, a non-competitive NMDA receptor 
antagonist, induces any changes in spatial learning memory and in the evoked 
potentials of the motor cortex in adult rats. 
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Material and Methods 
1. Animals 
Male Wistar rats (220-280g) were housed individually and had free access to food and water. 
All efforts were made to minimize animal suffering. The principles of laboratory animal care 
(NIH publication No. 85-23) and the protocol for animal care approved by the European 
Communities Council Directive of 24 November 1986 (86/609/EEC) were followed. 
KYN, KYNA, PROB, PTZ and MK-801 were obtained from Sigma (Steinheim, Germany), 
while the new compound G-KYNA (Fig. 2) was synthetized in the Institute of Medical 
Chemistry, University of Szeged. 
2. Drugs 
HO 
\ 
CH2 
HO 
Figure 2. The chemical structure of G-KYNA 
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3. Electrophysiology 
3.1. Hippocampal CAS area stimulation and contralateral CA1 area registration 
Surgical procedure: Animals were anaesthetized with urethane (1.25 g/kg, ¡.p.). In some cases, 
the tail vein of the animals was catheterized; in most of the experiments, however, the drugs 
were administered i.p. through a syringe implanted at the beginning of the experiments. For 
recordings in area CA1, a 2-3 mm-diameter hole was drilled over the dorsal hippocampus 
(3.0-3.8 mm posterior to the bregma and 1.8-2.3 mm lateral to the sagittal suture) and the 
recording electrode was lowered 2.4-3.6 mm from the cortical surface. Contralaterally, a 1-2-
mm hole was drilled for the CA3 stimulating electrode (3.7 mm posterior to the bregma, and 
3.3 mm lateral to the sagittal suture; final electrode depth 3.8 mm below the dura). Electrodes 
were lowered and final positions were adjusted so that the maximum CA1 population spike 
was obtained in response to contralateral CA3 stimulation (Fig. 3). The sites in areas CA1 and 
CA3 were confirmed histologically. Responses to a range of stimulus intensities were 
recorded under control conditions to produce an input-output curve by changing the duration 
(10-100 ps), using current (up to 200 pA) square pulses. Stimuli were triggered at low-
frequency (0.05 Hz). Response stability was monitored for 30 min prior to drug 
administration. The electrophysiological recording continued during the following 3-h 
recording period after drug administration. 
Drug administration: In pilot experiments, to examine the effects of pure KYN or PROB or 
PTZ, the animals were treated with various doses of these compounds, e.g. KYN was 
administered either intravenously (i.v.) or i.p. in doses of 5, 10, 50, 100, 200, 300 or 400 
mg/kg. Since i.p. and i.v. administration resulted in similar effects, i.p. administration was 
chosen in further studies, because it was more appropriate in the behavioral experiments. On 
the basis of the literature data (Vecsei et al., 1992; Wu et al., 1997b) and our pilot experiments 
on the dose-dependent effects of these compounds, we chose KYN in a dose of 300 mg/kg, 
PROB in a dose of 200 mg/kg and PTZ in a dose of 60 mg/kg throughout the main study. 
The chosen doses of KYN A and G-KYNA were also based on earlier pilot experiments, in 
which both KYN A and G-KYNA were administered i.v. or i.p., in doses of 17, 34, 68 or 136 
pmol/kg. Since i.p. and i.v. administration resulted in similar effects, i.p. administration was 
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chosen in further studies, because this seemed to be more appropriate in the scheduled 
behavioral experiments. We endeavoured to find the minimum doses that were still effective: 
accordingly, on the basis of these pilot experiments, both KYNA and G-KYNA were 
administered in a dose of 17 pmol/kg throughout the main study. 
3 2. Cortical evoked potentials 
Surgical procedure: Rats were anaesthetized with a mixture of Ketavet (10.0 mg/100 g) and 
Rompun (xylazine, 0.8 mg/100 g). On both sides, the primary motor cortex (MI) was exposed 
by craniotomy from about 2 mm posterior to 5 mm anterior from the bregma, and from 0.5 to 
5 mm lateral from the midline. In the course of the operation, we also exposed the right side 
facial nerve, including its postauricular branch. This was later transected, during the 
electrophysiological recordings. 
Electrical stimulation of the vibrissa pad or electromechanical vibrissa stimulation was 
employed to induce evoked potentials in the Mis in both hemispheres: the right whisker pad 
was stimulated electrically with bipolar needle electrodes (1 Hz; 0.3-ms duration, 150-200 pA) 
to evoke visible whisker movements, whilst for mechanical stimulation whiskers were 
deflected by using a multiangle electromechanical stimulator. To investigate paired pulse 
inhibition effects on the amplitudes of evoked potentials, a paired-pulse stimulation protocol 
was used (application of two electrical pulses with a 200-ms interstimulus interval). The ratio 
of the amplitudes of the evoked potentials elicited by the second versus the first stimulus was 
calculated and defined as the Q value (e.g. Q=EP2/EP1). Q<1 means that the second response 
was inhibited by the first one. 
4. Behaviour 
4.1. Open-field observations 
This behavioural test was carried out in a circular arena (80 cm in diameter); the height of the 
wall was 40 cm. Following administration of the compounds, the animals were observed for 5 
min. The stereotyped behaviour was characterized by the total time spent in grooming and 
20 
washing. Further parameters were monitored in different experiments: time spent in centre and 
periphery, rearing, defecation, the time (s) to the onset of grand mal seizures, the time (min) of 
death or ataxia. For ataxia, the ratings were ' I ' : awkward and jerky movements; '2 ' : stumbling 
or an awkward posture; '3 ' : falling, '4 ' : cannot move beyond a small area or supports weight 
on stomach or haunches; and '5 ' : unable to move except for twitching movements. 
4.2. Water-maze task 
The rats were trained in a large circular swimming pool (160 cm in diameter, 60 cm in height) 
filled with water to a depth of 35 cm. The water was at room temperature and was made 
opaque by the addition of 2 1 of milk. The pool was situated in a small rectangular room. The 
walls were equipped with a variety of spatial cues (pictures and a lamp emitting diffuse light), 
which remained unchanged during the experiment. The pool was divided into four quadrants, 
and a removable platform (8 cm in diameter) was hidden at one of four positions in the pool, 
exactly 25 cm from the side wall. The platform was 1.0 cm below the water surface and not 
visible for the swimming rat. The animal performed a block of four consecutive trials, all 
beginning at a fixed starting point (N, W, S or E). Trials ended either when the platform was 
found or when 60 s had elapsed. If the rats did not find the platform within 60 s, they were 
guided to it and left there for 15 s. They were then removed from the pool and either placed 
back after 15 s (intertrial interval) for the subsequent trial or returned to their home cages after 
being dried with a towel. The 5-day training consisted of one block of four trials per day, and 
for each trial the starting point varied in a random order such that no location recurred for a 
given day. Each trial was recorded and analysed by using a computer video tracking system. 
The video camera of the Ethovision System (Noldus) was mounted above the centre of the 
pool. 
To check the condition of the sensory and motor system of the animals, we can use the visual 
cue task. In these experiments, the platform is above the surface of the water so that it is 
visible for the swimming animals. If there is no significant difference in the performances of 
the treated and control animals in the visual cue task, we may conclude that the sensory and 
motor systems are in working order and any difference in performance is due to the impaired 
memory function. 
5. Data analysis 
For hippocampal evoked potentials, statistical significance was determined by means of the 
Student Most (p value set at 0.05 for significance). 
For the MI evoked potentials and the behavioral experiments, the statistical analysis was 
performed by using repeated measures ANOVA (SPSS for Windows 9.0). 
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Results 
1. Electrophysiology 
1.1. Hippocampal CA3 area stimulation and contralateral CAl area registration 
In these experiments, we decided to focus on the hippocampus: the evoked responses of the 
hippocampal neurones were chosen as end-point of these electrophysiological experiments 
because of the high concentrations of glutamate receptors on the dendrites of these neurones 
(Martin et al., 1993; Watanabe et al., 1993; Monyer et al., 1994) and because they receive 
glutamatergic afferents that can be stimulated preferentially in vivo (Fig. 3). In addition to 
electrophysiological experiments, the behavioral effects of these compounds (KYN, PROB 
and PTZ) were also studied in an open-field arena and in a water-maze task, which is likewise 
a suitable test for the hippocampal function. 
b 
|1 mV 
10 ms 
a 
Figure 3. Population spike recorded in the C A l area of the rat hippocampus, a: minimum point, b: 
maximum point of the response, b-a = amplitude of the population spike. 
1.1.1. Effects of KYN 
The responses of the area CAl pyramidal cells to contralateral CA3 stimulation were tested 
before and after the injection of KYN. KYN induced some changes in the population spike 
amplitudes in all cases. This occurred regardless of the mode of application, e.g. both i.v. and 
i.p. injections. However, the effects of KYN were controversial: in some experiments, the 
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systemically administered KYN resulted in a transient facilitation of the population spike 
amplitudes, while in other cases the same dose of this compound, administered in the same 
way, transiently decreased the amplitudes of the population spikes. These changes in 
amplitude rarely reached the level of significance (Fig. 4A). To summarize the overall data on 
KYN (300 mg/kg), it may be stated that KYN did not significantly change the amplitude of 
the evoked responses (Table I). 
11.2. Effects of PROB 
PROB is a known inhibitor of the transport of organic acid from the CSF (Cunningham et at., 
1981; Vecsei et ai, 1998) and hence can increase the KYN A concentration in the brain. When 
administered in a dose of 200 mg/kg, it did not cause an immediate significant change in the 
amplitude of the evoked population spike activity. In most cases, it resulted in a decrease in 
amplitude, but only 2 h after the administration (Fig. 4B). The overall data for all the animals 
in this group indicate a moderate inhibitory effect of PROB with a long delay (Table 1). 
/• 1.3. Effects of KYN+PROB 
The results were quite different when KYN was administered together with PROB. In all these 
cases, a significant change in amplitude of the population spikes occurred within 5-10 nhn. In 
some cases, a short, slight, transient increase in amplitude was observed after application of 
the drugs, but this was followed in all cases by a significant decrease in amplitude (Fig. 4C). 
In most cases, only the characteristic decrease in amplitude could be detected, as shown by the 
overall data for the animals in this group (Table 1). 
1.1.4. Effects of PTZ 
PTZ in a dose of 60 mg/kg induced a significant increase in amplitude of the population spikes 
registered in the CA1 area. This increase in amplitude started just after the drug 
administration, reached its plateau within 10 min and remained at the elevated level during the 
3-h registration period (Fig. 41) and Table 1). In one of the five PTZ-treated animals, the 
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amplitude increased to over 200% of the control level (Fig. 4D); in the other four animals, the 
increment changed by 115-150% of the control amplitude. The administration of PTZ (60 
mg/kg) never resulted in the death of the anaesthetized animals. 
1-1.5. Effects of KYN+PROB+PTZ 
It was stated above that PTZ (60 mg/kg) induced an immediate and significant increase in 
amplitude of the CA1 responses in all of the experiments. This PTZ-induced enhancement in 
amplitude was completely blocked in those animals in which KYN+PROB administration 
preceded the injection of PTZ (Fig. 4E). KYN (300 mg/kg) + PROB (200 mg/kg) were 
injected 2 h before the PTZ injection. The data obtained from the five PTZ-treated animals 
that received KYN+PROB prior to PTZ administration clearly demonstrate that KYN+PROB 
did not allow the development of the amplitude increase following PTZ administration (Table 
1). 
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KYN- PR08-PTZ 
Figure 4. Examples of the effects of the administered compounds on the population spike amplitudes 
recorded in the CA1 area. A: After 300 mg/kg KYN injection, hardly any marked change in amplitude was 
observed. B: 200 mg/kg PROB resulted in a decreased CA1 population spike with a 2-h delay. C: 
KYN+PROB injection resulted in a rapid and significant decrease in amplitude. D: 60 mg/kg PTZ resulted 
in a 200% increase in amplitude of the population spike. E: Effect of KYN+PROB+PTZ on the population 
spike recorded in the CA1 area. Ordinate: Spike amplitudes as percentages of the control. Abscissa: Time 
in min after drug injection. Each column represents the mean ± s.d. for 5 potentials. *p<0.05, **p<0.01. 
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Xxrn i ii 10 30 60 90 120 
150 180 
KYN 
V 4 
100 95.70+6.1 98.63+12.6 85.73+16.5 
87.91+15.5 89.17+19.2 82.76+13.9 90.74+19.6 
PROB 100 86.72+22.1 99.71+11.8 98.24+5.9 98.43+10.9 84.79+16.5 
74.90+22.9 68.56+23.2 
KYN'+ 
PROB 100 95,59+17.1 
88.67+5.2" 82.82+7.9** 72.98+9.1** 72.26+10.0** 72.85+19.4* 65.22+15.9** 
PTZ 100 125.9+10.4* 124.59+13.7* 112.23+4.1** 116.69+1.4** 112.55+6.3* 
116.23+1.9** 116.5+7.8* 
KYN-r 
PROB 
+PTZ 
100 93.11 + 15.7 90.42+16.9 82.74+18.7 87.46+17.3 83.81+15.7 
80.20+12.5** 88.43+11.9 
Table 1. Overall data on the effects of K Y N , P R O B , K Y N + P R O B , P T Z and K Y N + P R O B pretreatment 
with a P T Z infection 2 h later on the amplitudes of the population spikes recorded in the pyramidal layer 
Of the CA1 re l lnn of the hippocampus. C: Normalized amplitudes of responses before the drug injection 
G m ^ ^ l Z ™ ^ ) 30. 60, 90, 120, 150 and «80 min after the second injection. *p<0.05, 
**p<0.01. 
11.6. Effects of KYN A 
The responses of the area CA1 pyramidal cells to contralateral CA3 stimulation were tested 
before and after the injection of KYNA (17, 34, 68 or 136 pmol/kg). Marked effects of the i.p. 
injected drug were not observed in any of the treated animals, apart from some transient, 
inconsistent deviations from the control level: only a slight, if any decrease in the amplitude of 
the population spike (Fig. 5A and Table 2). 
/. 1.7. Effects of KYN A + PROB 
KYN A (17 pmol/kg) + PROB (200 mg/kg) administration together resulted in similar effects 
to those seen following PROB (200 mg/kg) administration alone. In most cases, when KYNA 
+ PROB were administered together, there was no change in the amplitudes of the responses 
during 1 h following the drug administration, but, with a 1.5-2-h delay, a slight decrease in 
amplitude was registered (Fig. 5B and Table 2). 
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11.8. Effects of G-KYNA 
In pilot experiments, G-KYNA was administered in doses of 17, 34, 68 or 136 pmol/kg. In a 
dose of 136 pmol/kg, G-KYNA administered either i.v. or i.p. resulted in 100% mortality 
within 5 min. Similarly, 68 pmol/kg G-KYNA administered i.v. resulted in a stoppage of 
breath, but the animals could be resuscitated. I.p. injection of this dose did not stop the 
breathing of the animals. These findings led us to reduce the dose of the drug to a level as low 
as possible which still resulted in a marked and clear-cut decrease in amplitude of the CA1 
pyramidal cell responses. We found that, in a dose of > 17 pmol/kg, G-KYNA induced 
consistent and appreciable decreases in the population spike amplitudes in all cases. This 
change started 50-60 min after drug administration, regardless of the mode of application (Fig. 
5C and Table 2). 
/ 1.9. Effects of G-KYNA+PROB 
G-KYNA (17 pmol/kg) administered together with PROB (200 mg/kg) resulted in a 
progressive and, by the end of the recording period, considerable decrease in amplitude of the 
CA1 population spikes. The decrease in amplitude began and became significant within 10-20 
min, and continued over the 3-h registration time (Fig. 5D and Table 2). In some of the 
experiments, the registration continued over 4.5 h. In these animals, the amplitude reduction 
was progressive throughout the whole experiment (Fig. 5E). 
28 
Figure 5. Examples of the effects of the administered compounds on the population spike amplitudes 
recorded in CA1. A: After KYNA injection, there were some decreases in amplitude, but these changes 
were not marked. B: After a transient increase, KYNA+PROB resulted in a decreased response with a 1.5-
2-h delay. C: G-KYNA injection resulted in marked and significant decreases in the CA1 population spike 
amplitudes with a 50-60-min delay. D: G-KYNA+PROB i.p. injection resulted in a considerable decrease 
in amplitude, shortly (10-20 min) after administration. This continuous decrease was maintained during 
the 4.5-h registration period (E). Ordinate: Spike amplitudes as percentages of the controls. Abscissa: 
Time in min after drug injection. Each column indicates the mean ± s.d. for 5 potentials. *p<0.05, 
**p<0.01. 
K Y N A - N H - G L U C • P R O B 
E % , 
¡tone's 
KYNA-NH-GLUC 
KYNA + PROB 
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C 0-30 min 30-60 min 60-90 min 90-120 min 120-150 min 150-180 min 
K Y N A 100 95.88+3.9 90.55+2.1 * 88.61 + 1.5 ** 90.08+2.8 * 87.20+2.6 * 87.39+2.4 * 
G - K Y N A 100 100.64 ±0.5 91.03+4.2 83.96+3.8 * 78.55+4.6 * 63.93+8.2 * 61.65+3.0 ** 
K Y N A + 
PROB 100 97,79+1,5 105.94+11.9 98.43+4.2 85.75+8.1 84.35+5.7 * 77.76+1.4 ** 
G - K Y N A 
+ P R O B 100 93.11+2.5 * 88.43+0.8 ** 81.47+2.9 ** 74.51+4.2 ** 73.50+2.9 ** 65.13+6.6 ** 
Table 2. Overall data on the effects of KYNA, G - K Y N A , K Y N A + P R O B and G - K Y N A + P R O B on the 
amplitudes of the population spikes recorded during 30-min blocks in the CA1 area. C: normalized 
amplitudes of responses before drug injections (100%). *p<0.05, **p<0.01. 
1-2. Cortical evoked potentials 
In addition to the barrel field of the contralateral somatosensory cortex, responses to 
trigeminal stimulation were also observed in the contralateral Ml (Mlc). In anaesthetized adult 
rats, both mechanical stimulation of the vibrissae and electrical stimulation of the whisker pad 
activate trigeminal afferents, which in turn produce a complex response pattern in a 
subpopulation of neurones in the Mlc. Moreover, it has been shown that the facial nerve cut 
induces disinhibition in an extended area of the MI, resulting in a facilitation of evoked 
responses. 
In the control rats, the somatosensory evoked potentials in the Mlc were rapidly modified by 
facial nerve transection. After I h, the amplitude of these potentials was significantly 
enhanced and the latencies of all the components had shortened. Responses with enhanced 
amplitudes could be observed throughout the 3- to 4-h recording session (Fig. 6A). Similar 
effects were found in the ipsilateral MI (Mli): in the control rats, stimulation of the trigeminal 
nerve or parts of it evoked very small potentials in the Mli; however, a few minutes after the 
facial nerve injury, evoked potentials could also be elicited with enhanced amplitude in this 
area, too. Their amplitude increased considerably within 1 h and remained high until the end 
of the experiments (3-4 h after denervation) (Fig. 6B). 
This was not the case in the rats treated with MK-801 as young animals. These animals 
received injections of 0.1 mg/kg MK-801 (dizocilpine) twice a day, starting on postnatal day 
(PND) 7 and lasting until PND 19. 
In all of these rats, trigeminal stimulation evoked potentials with high amplitude in the MIc 
(Fig. 7A1) and with small amplitude in the MI] (Fig. 7B1). This was similar to what was 
observed in the control rats. However, the facial nerve transection did not facilitate the evoked 
responses in the MI in either hemisphere. In a majority of the cases (60%), there was no 
change in the amplitudes or latencies of the evoked potentials following the facial nerve cut 
(Fig. 7A2, B2). In fact, in 40% of the cases studied, the amplitudes decreased or vanished 
from both Mis. 
The Q values were calculated in both the control and the MK-801-treated animals. In all the 
controls, the studies with a paired-pulse paradigm revealed disinhibition (Q > 1), while there 
was hardly any increase in Q after the facial nerve cut in the MK-801-treated animals (Q<1 in 
all cases) (Fig. 8). This is an indication that the Q values in the controls are changed 
significantly after facial nerve injury (disinhibition occurs), but Q did not change in the MK-
801-treated animals (no disinhibition). 
A1 
™fl! 
Time (ms) 
B1 
Time (ms) Time (ms) 
Figure 6. Responses evoked in the Mis in both hemispheres of a control rat by right side electrical vibrissa 
pad stimulation. Evoked potentials in the MIc recorded (Al ) before and (A2) 3 h after a facial nerve cut. 
Evoked potentials in the Mli (Bl ) before and (B2) 3 h after vibrissa pad stimulation. Ordinates are in 
mV/div. 
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Figure 7. Responses evoked in the M i s in both hemispheres in an MK-801 -treated rat by electrical vibrissa 
pad stimulation on the right side. Evoked potentials in the MIc ( A l ) before and (A2) 3 h after a facial 
nerve cut. Evoked potentials in the Mli ( B l ) before and (B2) 3 h after vibrissa pad stimulation. Ordinates 
are in mV/div. 
Time (min) Time (min) 
Figure 8. Q values calculated from the paired-pulse paradigm in the MIc of a control (A) and an MK-801-
treated (B) animal, displayed as a function of time. A: In the control animal, facial nerve transection 
produced a short (4 min) and, with some delay, a longer-lasting (35-40 min) elevation of Q. B: In the MK-
801-treated animal, transection of the facial nerve did not cause cortical disinhibition: the Q value 
remained <1. N7x: facial nerve transection 
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2- Behaviour 
2.1. Open-field observations 
3.1.1. Open-field observations after KYN, PROB and PTZ treatment 
The animals which received a pure PTZ injection developed seizures, culminating in 
generalized tonic-clonic activity, and died in the course of the 5-day experiment. Therefore, 
these animals did not take part in the open-field experiment. In the KYN+PROB+PTZ-treated 
group, the animals did not exhibit the development of any seizures in the course of the 5-day 
experiments and the mortality of these animals was very limited (Fig. 9). 
KYN + PROB + PTZ 
M P T Z 
r ICONTROL 
Figure 9. Cumulative number of dead animals in the groups of controls, PTZ-treated and K Y N + P R O B 
pretreated, then PTZ-injected animals during the 5-day experiment. Chronically administered PTZ (60 
mg/kg, i.p.) resulted in the death of all the animals in the PTZ-treated group during 5 days. With the 
exception of two animals, KYN+PROB pretreatment protected the rats from the death otherwise induced 
by the repeated PTZ injections. 
The animals in the KYN-, PROB-, KYN+PROB- and KYN+PROB+PTZ-treated groups did 
not display any significant difference between staying in the centre or at the periphery of the 
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arena: all animals preferred to stay at the periphery (Fig. 10A). Differences were observed in 
rearing, in stereotyped washing and in defecation activity between the controls and the other 
treated animals, but the differences in defecation activity were not significant (Fig. 10B,C,D). 
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Figure 10. Observations in an open field arena. A: Time (s) spent in the centre and at the periphery of the 
arena. No difference was found between the control and treated groups. The rats in all four groups 
preferred to stay at the periphery of the arena. B: Time (s) spent in rearing during the 5-min observation 
period. The animals after KYN, KYN+PROB or KYN+PROB+PTZ injection became calm and slowed 
down. C: the number of washings was decreased significantly only in the KYN+PROB+PTZ-treated group 
during the 5-min observation. D: Number of faeces produced during the 5-min period. Data are shown as 
means ± s.d. *p<0.05, **p<0.01. 
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2.1.2. Open-field observations after KYNA and G-KYNA treatment 
The behavioral effects of i.e.v. injected KYNA have already been well documented (Vecsei 
and Beal, 1990b; Vecsei and Beal, 1990a; Vecsei and Beal, 1991). In our experiments, we 
focused only on whether i.c.v. applied KYNA induced similar changes in behaviour under the 
present circumstances in order to make a comparison between the behaviour effects of these 
drugs. 0.3 pmol KYNA (i.c.v.) was injected into the rats to induce changes in behaviour. This 
amount of the compound induced characteristic changes in the behaviour of the animals after 
each of the consecutive injections. The animals developed grooming activity and ataxia after 
the injection. 
The effects of equimolar G-KYNA were also tested. The results of these experiments were 
very similar to those found after KYNA treatment (Fig. 11). Similar but more dramatic effects 
were observed after the injection in a dose of 0.6 pmol KYNA and G-KYNA (not shown). 
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Figure 11. Effects of i.c.v. administered 0.3 pmol KYNA and G-KYNA on grooming and ataxia in rats. The 
controls received the same volume (10 pi) of saline. The behaviour was examined between 10 and 15 min 
after drug administration. Both KYNA and G-KYNA resulted in the development of grooming and ataxia. 
*p<0.05. 
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2.2. Water-maze task 
2.2.1. Water-maze performance after KYN, PROB and PTZ treatment 
All five groups of animals (KYN, PROB, PTZ, KYN+PROB and KYN+PROB+PTZ) started 
to take part in the water-maze experiments which began 20 min after the treatments. From the 
very beginning, the performance throughout the 5 days revealed that the KYN+PROB+PTZ-
treated animals needed more time to reach the platform than did the controls. This tendency 
became marked from the sessions on day 2 and the difference then remained significant up to 
the end of the experiment. 
% ' 
200 -
150 -
100-
50 -
0 -
— • — CONTOL 
— • — KYN 
A KYN+PROB 
— K Y N + P R O B + P T Z 
Figure 12. Performance of five groups of animals in the water-maze test during the 5-day period (4 
trials/day). The escape latency at 100% (=mean for the controls) was 47 s. The number of PTZ-treated 
animals fell to 2 by day 4, and the evaluation of this group was therefore interrupted. *p<0.05, **p<0.01. 
Remark: On day 3, p<0.01 (control vs. KYNA+PROB+PTZ) and p<0.05 (control vs. PTZ). 
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The swimming strategies of the KYN+PROB+PTZ-treated animals and those in the other 
groups were not the same: the rats in the KYN+PROB+PTZ group spent more time swimming 
round the pool, near the wall, and demonstrated a poor performance throughout the 5-day trial. 
In contrast, the control animals displayed good progress in finding the hidden platform. 
Similarly, the animals in the KYN and KYN+PROB groups exhibited a good performance in 
the water-maze study. The PTZ-treated animals also started to reveal a good performance, but 
because of seizures and their high mortality rate, their testing was interrupted on day 3 (Fig. 
12). 
2.2.2. Water-maze performance after MK-801 treatment 
From the very beginning, the performance during the eight training sessions revealed that the 
MK-801 -treated animals needed more time to reach the platform. This tendency remained 
more or less unchanged during the eight sessions, though the difference in performance of the 
two groups was not significant in any one of the sessions (Fig. 13). 
Figure 13. Escape latencies (in seconds) of adult controls and MK-801-treated animals. The performance 
of the MK-801-treated rats (0.1 mg/kg, twice daily, PND 7-19) was slightly poorer than that of the saline-
treated controls. 
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It was interesting to observe that in the first trial in the first session the two groups needed 
approximately the same time to reach the platform. Later, the difference between the 
performances became larger, but did not attain the level of significance. 
The swimming strategies of the treated and control animals were not the same: the treated 
animals spent more time swimming round the pool, by the wall. The difference in 
performance, however, was not due to a difference in anxiety or swimming speed between the 
two groups. Taken together, the MK-801 -treated rats were capable of learning in the course of 
the sessions, but their performance tended to be poorer than that of the controls. 
To check the possibility of modification of the sensory and motor capabilities by MK-
801 treatment, a visual cue task was given to the animals in both groups. The visual cue task 
was performed equally well by both the controls and the MK-801-treated animals (Fig. 14). 
PND 101 PND 102 
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Figure 14. Escapes latencies for the two sessions of the visual cue task. The MK-801-treated animals and 
the controls performed equally well in this test. PND: postnatal day. 
On the basis of the water-maze analysis, it can be stated in general that the performances of 
the MK-801-treated rats in the spatial learning and memory task were slightly (but not 
significantly) poorer than those of the controls. However, the visual cue task was performed 
equally well by both the controls and the treated animals. 
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Discussion 
The normal concentration of KYNA in the brain is probably too low to influence the EAA 
receptors, and even under pathological conditions the data do not indicate that the 
concentration elevation will necessarily allow KYNA to influence the co-agonist site of the 
NMDA receptor. However, recent results reveal that the KYNA-sensitive presynaptic nACh 
receptors inhibit glutamate release at low concentration (30-100 nM) (Carpenedo et al, 2001). 
It may therefore be speculated that these nACh receptors contribute to the inhibitor}' effects of 
KYNA at low concentration. 
In 1984, Schwarcz's laboratory found that KYNA blocked both the neurodegeneration and the 
seizures caused by the local application of QUIN in the hippocampus and striatum (Foster et 
at., 1984) and this inhibition was seen in behavioral tests, too (Wirsching et al., 1989; 
Lekieffre et a/., 1990). 
It may be supposed that, if the KYNA content of the brain is high enough, it has a definite 
neuroprotective effect. 
First, we examined the effect of a relatively high systemic dose of KYNA precursor 
KYN which led to a non-physiological concentration of KYNA. This effect may be elevated 
by using PROB, which can prevent the discharge of the organic acids from the CSF. This 
proved effective: 300 mg/kg KYN (i.p.) slightly decreased the population spike amplitude of 
the c a 1 pyramidal cell responses. PROB had a stronger effect with a longer delay. The two 
compounds administered together resulted in a marked and significant decrease in amplitude 
of the population spike evoked on the CAI pyramidal cells. This effect is probably based on 
the inhibition of the NMDA receptors of the CAI pyramidal cells by the elevated level of 
KYNA in the brain tissue, as a consequence of peripheral KYN and PROB administration. 
PTZ is often used experimentally to induce seizures which mimic generalized clonic seizures 
in humans (Andre et al, 1998). Indeed, 60 mg/kg PTZ administered i.p. to anaesthetized rats 
resulted in a significant increase in amplitude of the CAI spike activity. This effect was 
completely compensated by pretreatment with KYN+PROB. 
In parallel with the electrophysiological results, we studied the behavioral effects of KYN 
administered together with PROB 2 h before the PTZ injection. This convulsive dose of PTZ 
(60 mg/kg) caused epileptic seizures and death in awake animals. It was found that 
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KYN+PROB pretreatment completely protects awake rats from PTZ-induced clonic-tonic 
seizures and death. Although they exhibited reduced rearing, washing and defecation activity, 
we did not observe any difference in behavior between the controls and the treated animals in 
an open-field arena, though they revealed a significantly impaired performance in the water-
maze task. 
KYNA is an EAA receptor antagonist which can partially act at both the a-amino-3-hydroxy-
5-methylisoxazole-4-propionic acid and NMD A subunits of glutamate receptors (Swartz et ai, 
1990; Stone, 1993). The overexcitation of these EAA receptors can lead to a high Ca : 
concentration and pathological processes, and finally start the apoptotic pathway in the cells. 
KYNA in high concentration is an effective neuroprotective agent, but its use is rather 
restricted because it has only a very limited ability to cross the BBB. 
A new KYNA derivative, G-KYNA, was synthetized in the Institute of Medical Chemistry, 
University of Szeged. We presumed that this can readily cross the BBB and provide an 
elevated KYNA level in the brain tissue. 
To check the similar effects of KYNA and its analogue G-KYNA, we tested these two 
compounds in behavioral and electrophysiological tasks. In agreement with the literature 
findings (Vecsei and Beal, 1990b; Vecsei and Beal, 1990a; Vecsei and Beal, 1991), the 
behavioral experiments revealed that i.e.v. microinjected KYNA induces stereotype behaviour 
and ataxia. Similar changes in behaviour were found after i.e. v. administered equimolar G-
KYNA. 
To examine whether G-KYNA can pass the BBB, we administered this drug i.v. and i.p. 
KYNA administered systemically in doses of 17, 34, 68 or 136 pmol/kg did not cause any 
observable change in the electrophysiological activity of the hippocampal CA1 region in 
anaesthetized animals. Against this, G-KYNA in a dose of 136 pmol/kg resulted in the death 
of the animals in all cases, while a dose of 68 pmol/kg (i.v.) induced the stoppage of breathing 
of the animals, though they could be resuscitated. A dose of G-KYNA as small as 17 pmol/kg 
was effective in reducing the CA3 stimulation-evoked activity of the CA1 pyramidal cells in the 
hippocampus. This effect was augmented when G-KYNA was administered together with 
PROB. PROB (200 mg/kg, i.p.) itself induced an increase in the brain KYNA content which is 
probably based only on the endogenous KYNA. A slight decrease in evoked activity was 
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observed with a long delay (1-1.5 h) in the experiments in which PROB or KYNA+PROB was 
injected i.p. into the rats. 
NMDA receptors play an important role in spatial learning and working memory (Vianna el 
al, 2000; Baker and Kim, 2002; Sargolini et al., 2003). The perinatal blockade of these 
receptors might have behavioral consequences when tests are made at a more advanced age 
(Gorter and de Bruin, 1992). In the course of our working, we tested the hypothesis that even a 
minimal conflict with NMDA receptors in the early critical age of life, which results in mild 
detectable change in daily behaviour, induces hidden but life-long dysfunctions that can be 
detected in different parts of the central nervous system. We chose a low dose of MK-801 (0.1 
mg/kg), injecting twice a day on PNDs 7-19, which caused a slight, not significant impairment 
of the performance in the water-maze task and produced hyperactivity, but did not impair the 
performance of the visual cue response of the adult animals. Later, these animals were used in 
electrophysiological examinations. 
An increasing number of results suggest that transiently reduced inhibition (e.g. after nerve 
injury) is a necessary, but not sufficient condition for the development of MI plasticity. The 
potential for plasticity in the MI has been closely linked to the function of NMDA receptors 
(Qiu et al., 1990). Moreover, it has been shown that a component of the field potentials 
evoked in the horizontal pathways of the rat motor cortex is mediated by these receptors and 
LTP can develop in these horizontal connections (Hess and Donoghue, 1994; Hess et al., 
1994). 
Simple recordings of evoked potentials in the Ml did not reveal significant differences 
between the controls and the MK-801-treated animals. Therefore, we tested a more complex 
phenomenon. The plasticity of evoked responses induced by facial nerve injury can be tested 
by the paired pulse paradigm (Toldi et al., 1999; Farkas et al., 2000). In the control rats, the 
responses evoked in the Mis of both hemispheres by continuous 1-Hz trigeminal stimulation 
were facilitated after facial nerve transection. This was not the case with the MK-801-treated 
animals. In a majority of the cases studied, the evoked responses did not change, while in 40% 
of the cases, continuous stimulation reduced the evoked responses recorded after facial nerve 
injury. 
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